PMID- 33190370
OWN - NLM
STAT- MEDLINE
DCOM- 20210524
LR  - 20210524
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 34
IP  - 1
DP  - 2021 Jan
TI  - Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset 
      of adverse events in dabrafenib plus trametinib combination therapy for advanced 
      melanoma.
PG  - e14544
LID - 10.1111/dth.14544 [doi]
AB  - Various adverse events (AEs) have been reported to occur at a high rate in 
      patients treated with dabrafenib plus trametinib (D + T) combination therapy. 
      Among such AEs, the incidence of pyrexia was highest among the series of AEs in 
      patients treated with D + T combination therapy. Although little is known about 
      the mechanisms of pyrexia caused by D + T combination therapy, a recent report 
      suggested that sCD163, as well as interferon-inducible chemokines (CXCL9, CXCL10, 
      CXCL11), might correlate with pyrexia caused by encorafenib plus binimetinib 
      combination therapy. In addition to these soluble factors, CXCL5 is a biomarker 
      for predicting immune-related AEs in melanoma patients treated with nivolumab. 
      From the above findings, we hypothesized that these soluble factors might also 
      correlate with the onset of AEs in D + T combination therapy. The serum levels of 
      sCD163 were increased in patients with pyrexia in parallel with their severity, 
      whereas the serum levels of CXCL5 were increased in patients without pyrexia. 
      Moreover, increased levels of CXCL9, CXCL10, and CXCL11 were prominent in 
      patients with AEs over G2 levels. As these chemokines recruit Th1, Th17, and 
      activated CD8+ T cells, increased serum levels of these chemokines might 
      correlate with the positive feedback of inflammatory reactions related to AEs.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Amagai, Ryo
AU  - Amagai R
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Fujimura, Taku
AU  - Fujimura T
AUID- ORCID: 0000-0001-6809-5833
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Muto, Yusuke
AU  - Muto Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Kambayashi, Yumi
AU  - Kambayashi Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Furudate, Sadanori
AU  - Furudate S
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Ohuchi, Kentaro
AU  - Ohuchi K
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Okuma, Takami
AU  - Okuma T
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Hashimoto, Akira
AU  - Hashimoto A
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Aiba, Setsuya
AU  - Aiba S
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
LA  - eng
GR  - 19cm0106434h0002/Japan Agency for Medical Research and Development/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201122
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Biomarkers)
RN  - 0 (Chemokines)
RN  - 0 (Imidazoles)
RN  - 0 (Oximes)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 33E86K87QN (trametinib)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - QGP4HA4G1B (dabrafenib)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Biomarkers
MH  - Chemokines/therapeutic use
MH  - Humans
MH  - Imidazoles
MH  - *Melanoma/drug therapy
MH  - Mutation
MH  - Oximes
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Pyridones
MH  - Pyrimidinones
MH  - *Skin Neoplasms/drug therapy
OTO - NOTNLM
OT  - IFN-gamma-induced chemokines
OT  - adult-onset Still's disease
OT  - adverse events
OT  - dabrafenib plus trametinib combined therapy
OT  - sCD163
EDAT- 2020/11/16 06:00
MHDA- 2021/05/25 06:00
CRDT- 2020/11/15 20:38
PHST- 2020/09/02 00:00 [received]
PHST- 2020/10/31 00:00 [revised]
PHST- 2020/11/11 00:00 [accepted]
PHST- 2020/11/16 06:00 [pubmed]
PHST- 2021/05/25 06:00 [medline]
PHST- 2020/11/15 20:38 [entrez]
AID - 10.1111/dth.14544 [doi]
PST - ppublish
SO  - Dermatol Ther. 2021 Jan;34(1):e14544. doi: 10.1111/dth.14544. Epub 2020 Nov 22.